Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosylate plus propofol versus remimazolam or propofol alone for painless gastrointestinal endoscopy
ChiCTR2200060510Phase 4Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam and propofol in Peptic ulcer disease (PUD) (3 arms), sponsored by Changzhou Second People's Hospital. Primary endpoint: Hemodynamics. Planned start May 2022; status: not yet recruiting.
02
Drugs
remimazolampropofol
03
Conditions
Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on ChiCTR2200060510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060510.